Mukund Paravasthu Sells 43,246 Shares of NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited (NASDAQ:NVCR) COO Mukund Paravasthu sold 43,246 shares of NovoCure stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $13.77, for a total value of $595,497.42. Following the completion of the transaction, the chief operating officer owned 72,832 shares of the company’s stock, valued at approximately $1,002,896.64. The trade was a 37.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Mukund Paravasthu also recently made the following trade(s):

• On Wednesday, March 4th, Mukund Paravasthu sold 5,377 shares of NovoCure stock. The stock was sold at an average price of $13.31, for a total value of $71,567.87.

NovoCure Stock Performance

Shares of NASDAQ:NVCR opened at $13.04 on Friday. The business has a fifty day moving average of $12.74 and a 200-day moving average of $12.71. The firm has a market cap of $1.48 billion, a PE ratio of -10.69 and a beta of 0.71. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.50 and a current ratio of 2.90. NovoCure Limited has a twelve month low of $9.82 and a twelve month high of $21.55.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. The firm had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The company’s revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.61) EPS. On average, equities research analysts predict that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

Hedge Funds Weigh In On NovoCure

Hedge funds and other institutional investors have recently bought and sold shares of the business. Empowered Funds LLC acquired a new stake in NovoCure during the 4th quarter worth $33,000. SJS Investment Consulting Inc. acquired a new position in shares of NovoCure in the 3rd quarter valued at $41,000. Kestra Advisory Services LLC bought a new position in shares of NovoCure in the 4th quarter worth $49,000. Larson Financial Group LLC boosted its position in shares of NovoCure by 662.1% in the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of NovoCure during the second quarter worth $88,000. 84.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NVCR has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. HC Wainwright lifted their target price on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wedbush restated a “neutral” rating and set a $18.00 target price on shares of NovoCure in a research report on Thursday, January 15th. Finally, Evercore set a $20.00 price target on NovoCure in a research note on Monday, January 5th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $26.93.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.